LEN vs PTGX · rev $14.56B vs rev $269.8M
LEN (LEN) versus Protagonist Therapeutics Inc (PTGX) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
Latest reported LEN revenue for 2026-05-31 was $14.56B. Net income was $534.2M. LEN currently screens at market cap $0.
Latest reported PTGX revenue for 2026-06-30 was $269.8M. Net income was $166.6M. PTGX currently screens at market cap $7.25B.
LEN currently screens at market cap $0. PTGX currently screens at market cap $7.25B.
Not investment advice. Open the LEN and PTGX stock pages for the full models.
Not investment advice.